Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shen Yunli, Zeng Chunyu, Sun Yingxian, Wang Jian'an, Yu Bo, Cheng Xiang, Guo Xiaogang, Wang Dao Wen, Li Yue, Han Wei, Zhou Bingqing, Sheng Hongzhuan, Huang Zhaoqi, Li Yigang, Fu Guosheng, Zhang Jidong, Xie Duanyang, Liang Dandan, Liu Yi, Yang Bing, Zhang Qi, Duan Ran, Li Hongxiao, Zhang Baowei, Wu Yizhang, Zheng Liang, He Jia, Liu Shenglin, Yin Dechun, Sun Guozhe, Zhang Shu, Guo Xiaofan, Zhang Min, Wang Yiyi, Hu Xiajun, Zeng Jing, Yang Xiaoli, Li Shufeng, Li Ning, Hu Feng, Wang Haifeng, Hu Xinyang, Wang Yaping, Zeng Cong, Wang Kai, Yang Jian, Wang Yan, Lai Jinsheng, Wang Luyun, Xiong Ke, Wang Guanghua, Zou Qicheng, Shao Beihua, Chen Zhiwen, Wu Yahan, Leng Junwei, Pu Jun, Ma Changsheng, Chen Yi-Han
Аннотация
METHODS: We conducted an investigator-initiated, phase 2, multicenter, randomized, double-blind, placebo-controlled trial. Symptomatic adults with frequent PACs (≥1000/24 h) were randomly assigned to receive memantine or placebo for 6 weeks. The primary end point was the percentage change in mean 24-hour PAC count from baseline to the end of treatment. The primary analysis was performed in the intention-to-treat population. Prespecified secondary end points included the responder rate (≥50% PAC reduction), percentage change in nonsustained atrial tachycardia burden, and cumulative incidence of new-onset atrial fibrillation.
RESULTS: Among 241 patients included in the efficacy analysis, memantine resulted in a greater reduction in PAC count than placebo (between-group difference, 47.1 percentage points; P=0.0045). The responder rate was higher with memantine than with placebo (52.4% versus 23.1%; P<0.0001). Memantine also reduced nonsustained atrial tachycardia burden (between-group difference, 30.98 percentage points; P=0.0043) and was associated with a lower cumulative incidence of new-onset atrial fibrillation (4.8% versus 23.9%; P<0.0001). No clinically meaningful differences were observed in electrocardiographic intervals or left ventricular function, and no drug-related serious adverse events occurred.
CONCLUSIONS: In patients with frequent symptomatic PACs, memantine reduced atrial ectopy and atrial tachyarrhythmia burden and demonstrated a favorable safety profile. These findings provide proof of concept for a novel, non-ion channel-based therapeutic strategy targeting the cardiac glutamatergic system.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06501638.